Warnex Medical Laboratories has announced the launch of Warnex's Septin9 blood-testing service for colorectal cancer in Canada.
The Septin9 test is based on Epigenomics's biomarker Septin9 and DNA methylation technologies.
Prior to its launch, Warnex's Septin9 test was independently developed and validated using clinical blood samples from colorectal cancer patients and individuals with no apparent disease as verified by colonoscopy.
